

Prior authorization requirements for injectable/infusible drugs: mepolizumab (Nucala) and reslizumab (Cinqair)

Effective September 1, 2018, PA requirements will change for injectable/infusible drugs mepolizumab (Nucala[®]) and reslizumab (Cinqair[®]). Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- Mepolizumab (Nucala) — injection, 1 mg (J2182)
- Reslizumab (Cinqair) — injection, 1 mg (J2786)

To request PA, you may use one of the following methods:

- **Fax: 1-855-402-6983**
- **Phone: 1-866-655-7423**

Not all PA requirements are listed here. PA requirements are available to contracted and noncontracted providers on our provider website (www.unicare.com > Providers > State Sponsored Plan providers > West Virginia - Medicaid Managed Care > Authorization and Preservice Review > Precertification Look UP Tool [PLUTO]). Providers may also call us at **1-800-782-0095** for PA requirements.